Ascentage Pharma

Ascentage Pharma (6855.HK)  announced its 2024 interim results. During the reporting period, Ascentage Pharma continued to execute its global innovation strategy, having achieved breakthroughs across various aspects of its business including external collaborations, commercialization, and clinical development. In particular, the company has set a new record with its revenue for the first half of 2024 and reported profit for the first time. read more: https://lnkd.in/eDsHtP6W

Ascentage Pharma (6855.HK) 2024 Interim Results Presentation Invitation. Please scan the QR code for registration.

Phase III Study of Lisaftoclax in Newly-Diagnosed MDS Cleared Ascentage Pharma (6855.HK) announced today it has been cleared by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) to initiate a registrational Phase III study of lisaftoclax (APG-2575), one of the company’s key drug candidates, in combination with azacitidine (AZA) for the first-line treatment of newly-diagnosed patients with higher-risk myelodysplastic syndrome (MDS). This clears the fourth registrational Phase III study of lisaftoclax, marking another major milestone in the clinical development of the drug. Read More: https://lnkd.in/ecbXi6QN

Olverembatinib Approved for Commercialization in Macau China Ascentage Pharma (6855.HK) announced today that its novel BCR-ABL1 tyrosine kinase inhibitor (TKI), olverembatinib, has been approved by the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region (SAR) of the People’s Republic of China for the treatment of adult patients with tyrosine kinase inhibitors (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) or accelerated-phase CML (CML-AP) harboring the T315I mutation; and adult patients with CML-CP resistant to and/or intolerant of first-and second-generation TKIs. This approval marks another major milestone for olverembatinib following initial approvals granted to the drug in the Chinese mainland for the above indications. Read More: https://lnkd.in/eXyHJYGg

Ascentage Received US$100 Million Option Payment from Takeda On June 14, 2024, Ascentage Pharma and Takeda entered into an Exclusive Option Agreement that granted Takeda an exclusive option to enter into an exclusive license agreement for olverembatinib. The Exclusive Option Agreement calls for Ascentage Pharma to receive an option payment of US$100 million and provides for Ascentage Pharma to be eligible for an option exercise fee and additional potential milestone payments of up to approximately US$1.2 billion and double-digit royalties on annual sales. Read more: https://lnkd.in/eygfu2VS

Ascentage Received US$75M Equity Investment by Takeda Ascentage Pharma (6855.HK) announced today that the agreed equity investment by Takeda has been closed on June 20, 2024, with all proceeds already received. Pursuant to the terms of the Agreement, Ascentage Pharma has allotted and issued an aggregate of 24,307,322 subscription shares to Takeda International at the share purchase price of HK$24.09850 (equivalent to approximately US$3.08549). read more：https://lnkd.in/dU29dwRc

Ascentage Pharma Group International (the “Company” or “Ascentage Pharma”) is pleased to announce that it has released updated results from three studies of olverembatinib (HQP1351), the first China-approved third-generation BCR-ABL inhibitor and updated data of lisaftoclax (APG-2575), one of its key drug candidates, combined with novel therapeutic regimens in patients with relapsed/refractory (R/R) multiple myeloma (MM) or immunoglobulin light-chain (AL) amyloidosis, in poster presentations at the 2024 European Hematology Association Hybrid Congress (EHA 2024), taking place in Madrid, Europe. Read More: https://lnkd.in/e6739D2g

Inside Information Confidential Filing of Draft Registration Statement on Form F-1 The board (the “Board”) of directors (the “Directors”) of the Company is announcing that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering (the “Proposed Initial Public Offering”) of American depositary shares (the “ADSs”) representing its ordinary shares (the “Shares”). The number of Shares and ADSs to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to occur after the SEC completes its review process, subject to market and other conditions. Read more: https://lnkd.in/ePJpYd8P

Ascentage Pharma Signs Option Agreement with Takeda Ascentage Pharma (6855 HK) announced today the signing of an option agreement with Takeda to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers. If exercised, the option would allow Takeda to license exclusive global rights to develop and commercialize olverembatinib in all territories outside of among others, China. read more：https://lnkd.in/eEBnc3cd

Ascentage Pharma (6855.HK) announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Product Administration (NMPA) has approved a global registrational Phase III study of the company’s novel drug candidate olverembatinib (HQP1351), in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) who had failed prior systemic treatment. This approval marks a major milestone in Ascentage Pharma’s clinical development in solid tumors.  read more：https://lnkd.in/gUkbcdeT